225 related articles for article (PubMed ID: 25855582)
1. Significant biomarkers for the management of hepatocellular carcinoma.
Kondo Y; Kimura O; Shimosegawa T
Clin J Gastroenterol; 2015 Jun; 8(3):109-15. PubMed ID: 25855582
[TBL] [Abstract][Full Text] [Related]
2. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar.
Taketa K; Okada S; Win N; Hlaing NK; Wind KM
Acta Med Okayama; 2002 Dec; 56(6):317-20. PubMed ID: 12685861
[TBL] [Abstract][Full Text] [Related]
5. Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma.
Takikawa Y; Suzuki K; Yamazaki K; Goto T; Madarame T; Miura Y; Yoshida T; Kashiwabara T; Sato S
J Gastroenterol Hepatol; 1992; 7(1):1-6. PubMed ID: 1371940
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
[TBL] [Abstract][Full Text] [Related]
7. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma.
Park H; Kim SU; Park JY; Kim DY; Ahn SH; Chon CY; Han KH; Seong J
Liver Int; 2014 Feb; 34(2):313-21. PubMed ID: 23895043
[TBL] [Abstract][Full Text] [Related]
9. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.
Xing H; Zheng YJ; Han J; Zhang H; Li ZL; Lau WY; Shen F; Yang T
Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):487-495. PubMed ID: 30257796
[TBL] [Abstract][Full Text] [Related]
10. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Han KH; Kim DY
Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
[TBL] [Abstract][Full Text] [Related]
11. [The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma].
Zhang JW; Guan LY; E CY; Yang JH; Xuan W; Meng ZH; Li W
Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):776-781. PubMed ID: 32993265
[No Abstract] [Full Text] [Related]
12. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
[TBL] [Abstract][Full Text] [Related]
13. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
Kudo M
J Gastroenterol Hepatol; 2010 Mar; 25(3):439-52. PubMed ID: 20370723
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients.
Yu R; Xiang X; Tan Z; Zhou Y; Wang H; Deng G
Sci Rep; 2016 Oct; 6():35050. PubMed ID: 27731353
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.
Malik J; Klammer M; Rolny V; Chan HL; Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; Swiatek-de Lange M
World J Gastroenterol; 2022 Aug; 28(29):3917-3933. PubMed ID: 36157551
[TBL] [Abstract][Full Text] [Related]
16. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.
Wong RJ; Ahmed A; Gish RG
Clin Liver Dis; 2015 May; 19(2):309-23. PubMed ID: 25921665
[TBL] [Abstract][Full Text] [Related]
17. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
19. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
20. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
Morota K; Nakagawa M; Sekiya R; Hemken PM; Sokoll LJ; Elliott D; Chan DW; Dowell BL
Clin Chem Lab Med; 2011 Apr; 49(4):711-8. PubMed ID: 21231906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]